27
Participants
Start Date
December 7, 2020
Primary Completion Date
August 31, 2026
Study Completion Date
August 31, 2027
Hypofractionated radiotherapy
Radiation boost (RT) 7 Gy x 1 fraction on Day -14/Day -7 (arm 1) or Day -7/Day -14
Pembrolizumab infusion
Pembrolizumab infusion flat dosing 200 mg delivered over 30 minutes.
Blood and tissue sampling
Blood will be collected for laboratory studies and complete correlative studies to examine how the subject's immune system is responding to treatment. On day 0, samples of tumor and any lymph nodes removed from armpit will be analyzed by the UPenn Department of Pathology according to standard practice.
RECRUITING
Perelman Center for Advanced Medicine, Philadelphia
Abramson Cancer Center at Penn Medicine
OTHER